RT Book, Section
A1 Cascone, Tina
A1 Gold, Kathryn A.
A1 Glisson, Bonnie S.
A2 Kantarjian, Hagop M.
A2 Wolff, Robert A.
SR Print(0)
ID 1126741555
T1 Small Cell Carcinoma of the Lung
T2 The MD Anderson Manual of Medical Oncology, 3e
YR 2016
FD 2016
PB McGraw-Hill Medical
PP New York, NY
SN 9780071847940
LK accessmedicine.mhmedical.com/content.aspx?aid=1126741555
RD 2024/04/24
AB Small  cell  lung  cancer  (SCLC)  is  an  aggressive  bronchogenic  carcinoma  diagnosed  in  14%  of  all  patients  with  lung  cancer,  accounting  for  approximately  30,000  new  cases  annually  in  the  United  States  (1).  It  is  distinguished  from  non–small  cell  lung  cancer  (NSCLC)  by  its  rapid  doubling  time,  high  proliferative  fraction,  and  early  development  of  metastases.  Regional  lymph  node  involvement  or  distant  metastasis  is  present  in  90%  or  more  of  patients  at  diagnosis.  Historically,  SCLC  has  been  staged  as  limited  disease  (LD),  which  is  confined  to  the  ipsilateral  thorax  of  origin  and  regional  nodes,  versus  extensive  disease  (ED).  The  recent  International  Association  for  the  Study  of  Lung  Cancer  (IASLC)  staging  project  and  American  Joint  Committee  on  Cancer/International  Union  Against  Cancer  (AJCC/UICC)  seventh  edition  suggest  use  of  the  tumor,  node,  metastasis  (TNM)  system  for  the  staging  of  SCLC  (2).  Clinically,  the  limited-  and  extensive-stage  classification  is  practical  given  that  most  patients  present  with  advanced  disease  (stages  III-IV)  and  are  only  rarely  candidates  for  resection.